-
North Korean women footballers arrive in South Korea: AFP
-
Rousey demolishes Carano in MMA comeback fight
-
German 'chemical town' fears impact of industrial decline
-
Qantas flight diverted after man bites flight attendant
-
India scrambles to steady rupee as oil shock bites
-
McGregor to make UFC return with Holloway rematch
-
WHO declares international emergency as Ebola outbreak kills more than 80 in DR Congo
-
Crackdown in Southeast Asia pushes scam networks to Sri Lanka
-
'Geek' hangout to tourist draw: Japan's maid cafes
-
Spacecraft to probe how Earth fends off raging solar winds
-
Bulgaria's 'Bangaranga' wins Eurovision, with Israel second
-
Musk wants SpaceX to go public. Here's how it works
-
Big risks and rewards in upcoming IPOs at SpaceX, OpenAI, Anthropic
-
Pal in last duo could ease nerves for PGA leader Smalley
-
Ronaldo suffers more agony as Al Nassr lose 1-0 in AFC final
-
Venezuela expels Maduro ally Alex Saab to US again
-
Rising star Woad in charge at LPGA Queen City Championship
-
Rodgers returning with Steelers for 22nd season
-
Rahm on PGA: 'It's a battle out there'
-
Dara: dancing to victory at Eurovision
-
As U.S. Markets Continue Surging to Historic All-Time Highs, ELEKTROS Believes This Could Be a Defining Opportunity for Penny Stock Investors Seeking Exposure to the Future of Lithium Mining, EV Infrastructure, and Next-Generation Electrification Technologies
-
Napoleon Solo wins 151st Preakness Stakes
-
Last 10 Eurovision winners
-
Smalley grabs PGA lead as wild final day showdown looms
-
Canada cruise passenger 'presumptive positive' for hantavirus
-
Five share PGA lead logjam with wild final day in store
-
Decision time at full-throttle Eurovision final
-
McIlroy charges into the hunt for epic major comeback win
-
Iran confirms squad heading to Turkey for World Cup preparation
-
Bolivian police clash with protesters blocking roads
-
Eurovision final kicks off with Viennese grandeur
-
Svitolina sees off Gauff to win Italian Open, Sinner in men's title showdown
-
Alonso set for appointment as Chelsea manager: reports
-
Spanish star Javier Bardem says 'narrative changing' on Gaza
-
Gujarat miss out on top spot as Kolkata stay alive in IPL
-
Charging McIlroy grabs share of the PGA lead
-
Rwanda genocide suspect Kabuga dead: court
-
No beer for City stars despite FA Cup win, says Guardiola
-
Modi oversees semi-conductor deal on Dutch trip
-
Americans 'should demonstrate like the French,' says Woody Harrelson
-
Vienna abuzz for Eurovision final
-
McFarlane eyes 'massive' Spurs clash after FA Cup final defeat
-
Scuffles from Europe to NYC as Swatch sale descends into chaos
-
Bielle-Biarrey helps Bordeaux-Begles avoid Top 14 slip-up before Champions Cup final
-
Man City still dream of Premier League glory after FA Cup win: Silva
-
Hearts broken as O'Neill summons Celtic's champion spirit
-
'Dance all night': Harry Styles kicks off World Tour in Amsterdam
-
Kane hits hat-trick, St. Pauli relegated from Bundesliga
-
Semenyo's magic moment fires Man City to FA Cup final win over Chelsea
-
Football back on war-battered pitches in Sudan capital
US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
L.Durand--AMWN